Heal Venture Lab

Heal Venture Lab (HVL) is a Singapore-based healthcare venture platform operating at the intersection of capital, commercialization, and cross-border market entry across Asia and the United States. HVL works with healthcare companies, hospital groups, universities, and investors to support high-conviction decision-making — whether to invest, license, scale internationally, or walk away — before committing capital, leadership time, or institutional reputation. We operate with our own investor and LP network and engage selectively on portfolio focus, market validation, and deal readiness, particularly in complex Asian markets where signal-to-noise is high and execution risk is often mispriced. Current therapeutic focus - Oncology - Metabolic disease & obesity - Immunology - Other high value therapeutic areas for biopharma and medtech Across these areas, we prioritize biotech and medtech assets with clear translational pathways, commercial traction, and relevance to real-world healthcare systems. HVL is intentionally structured as a venture platform, not a general advisory. Our work is upstream, scoped, and decision-oriented — focused on clarity, optionality, and disciplined capital deployment rather than volume or outcomes.